SCHEMBL7211474

SCHEMBL7211474

NS(=O)(=O)c1sccc1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRB P24530 1/20 0.48
EDNRA P25101 1/20 0.48
CA2 P00918 10/20 0.46
CA1 P00915 9/20 0.46
CA9 Q16790 5/20 0.46
CA12 O43570 4/20 0.46
CA14 Q9ULX7 3/20 0.46
CA5A P35218 2/20 0.42
BCL2 P10415 1/20 0.41
BCL2L1 Q07817 1/20 0.41
CA4 P22748 2/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
CA7 P43166 2/20 0.39
HTR2A P28223 1/20 0.39
CALM1 P0DP23 1/20 0.38
CA3 P07451 1/20 0.38
CA6 P23280 1/20 0.38
PLA2G7 Q13093 1/20 0.38
CA13 Q8N1Q1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6969462 0.84 EDNRB (0.47) EDNRBEDNRACA2CA1CA9
SCHEMBL7217744 0.84 CA2 (0.46) EDNRBEDNRACA2CA1CA9
SCHEMBL7336846 0.84 EDNRB (0.47) EDNRBEDNRACA2CA1CA9
SCHEMBL28943849 0.84 EDNRB (0.47) EDNRBEDNRACA2CA1BCL2
SCHEMBL28204598 0.79 CA2 (0.44) CA2CA1CA9CA12CA14
SCHEMBL28204012 0.78 DHFR (0.46) CA2CA1CA9CA14CA7
SCHEMBL5655444 0.75 CA2 (0.42) CA2CA1CA9CA12CA14
SCHEMBL31384246 0.74 ENPP1 (0.58)
SCHEMBL9273452 0.74 CA2 (0.45) CA2CA1CA9CA12CA14
SCHEMBL4358027 0.73 CA2 (0.41) CA2CA1CA9CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852135-A N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-10-29 CN disclosed
US-6613804-B2 Treatment of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock ENCYSIVE PHARMACEUTICALS, INC. 2003-09-02 US disclosed
US-6342610-B2 COMPOUNDS SUCH AS N-(4-BROMO-3-METHYL-5-ISOXAZOLYL)-2-N-BENZYLBENZO(B)THIOPHENE-3-SUFONAMIDE ADMINISTERED AS ENDOTHELIN PEPTIDE RECEPTOR ANTAGONISTS TEXAS BIOTECHNOLOGY CORP. 2002-01-29 US disclosed
US-6331637-B1 N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORPORATION 2001-12-18 US disclosed
EP-0819125-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-01-21 EP disclosed
WO-1996031492-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1996-10-10 WO disclosed